HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $20 price target on the stock.
November 14, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating and a $20 price target for Ocuphire Pharma, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can lead to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100